Randomized trial of dacarbazine versus bleomycin, vincristine, lomustine and dacarbazine (BOLD) chemotherapy combined with natural or recombinant interferon-α in patients with advanced melanoma

Melanoma Research

Volumn 15, Issue 4, 2005, Pages 291-296

  Vuoristo, Meri Sisko ^a,f   Hahka Kemppinen, Marjo ^b   Parvinen, Leena Maija ^c   Pyrhönen, Seppo ^c   Seppä, Hanna ^d   Korpela, Merja ^e   Kellokumpu Lehtinen, Pirkko ^a  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c TURKU UNIVERSITY HOSPITAL   (Finland)

^d KUOPIO UNIVERSITY HOSPITAL   (Finland)

^e OULU UNIVERSITY HOSPITAL   (Finland)

^f TAMPERE UNIVERSITY HOSPITAL   (Finland)

Author keywords

BOLD; Chemoimmunotherapy; Dacarbazine; DOBC; Interferon; Melanoma; Randomized trial

Indexed keywords

ALPHA INTERFERON; BLEOMYCIN; DACARBAZINE; FINNFERON ALPHA; LOMUSTINE; RECOMBINANT ALPHA2B INTERFERON; VINCRISTINE;

ADOLESCENT; ADULT; ADVANCED CANCER; AGED; ALLERGY; ALOPECIA; ANEMIA; ARTICLE; BLEEDING; BONE METASTASIS; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; EPIGASTRIC PAIN; FATIGUE; FEMALE; FEVER; HEART ARRHYTHMIA; HEART FAILURE; HUMAN; HYPOTHYROIDISM; IMPAIRED GLUCOSE TOLERANCE; INFECTION; LIVER TOXICITY; LUNG FIBROSIS; LUNG METASTASIS; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; MELANOMA; MOOD DISORDER; MULTICENTER STUDY; MYALGIA; MYELODYSPLASTIC SYNDROME; NAUSEA AND VOMITING; NEUROTOXICITY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOFT TISSUE METASTASIS; STOMATITIS; THORAX PAIN; THROMBOCYTOPENIA; TREATMENT OUTCOME; VISCERAL METASTASIS; WEIGHT REDUCTION;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; DACARBAZINE; FEMALE; HUMANS; INTERFERON TYPE I, RECOMBINANT; INTERFERON-ALPHA; LOMUSTINE; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; SKIN NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VINCRISTINE;

EID: 23744493073     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-200508000-00010     Document Type: Article

References (29)

1. Li Y, McClay EF. Systemic chemotherapy for the treatment of metastatic melanoma. Semin Oncol 2002; 29:413-426.
2. Bajetta E, Del Vecchio M, Bernard-Marty C, Vitali M, Buzzoni R, Rixe O, et al. Metastatic melanoma: chemotherapy. Semin Oncol 2002; 29:427-445.
3. Costanza ME, Nathanson L, Lenhard R, Wolter J, Colsky J, Oberfield RA, et al. Therapy of malignant melanoma with an imidazole carboxamide and bis-chloroethyl nitrosourea. Cancer 1972; 30:1457-1461.
4. Lopez M, Perno CF, Di Lauro L, Papaldo P, Ganzina F, Barduagni A. Controlled study of DTIC versus DTIC plus epirubicin in metastatic malignant melanoma. Invest New Drugs 1984; 2:319-322.
5. Ringborg U, Rudenstam C-M, Hansson J, Hafström L, Stenstam B, Strander H. Dacarbazine versus dacarbazine-vindesine in disseminated malignant melanoma: a randomized phase II study. Med Oncol Tumor Pharmacother 1989; 6:285-289.
6. Moon JH, Gailani S, Cooper MR, Hayes DM, Rege VB, Blom J, et al. Comparison of the combination of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and vincristine with two dose schedules of 5-(3,3-dimethyl-1-triazino) imidazole 4-carboxamide (DTIC) in the treatment of disseminated malignant melanoma. Cancer 1975; 35:368-371.
7. Bellet RE, Mastrangelo MJ, Laucius JF, Bodurtha AJ. Randomized prospective trial of DTIC (NSC-45388) alone versus BCNU (NSC-409962) plus vincristine (NSC-67574) in the treatment of metastatic malignant melanoma. Cancer Treat Rep 1976; 60:595-600.
8. Carter RD, Krementz ET, Hill II GJ, Metter GE, Fletcher WS, Golomb FM, et al. DTIC (NSC-45388) and combination therapy for melanoma. I. Studies with DTIC, BCNU (NSC-409962), CCNU (NSC-79037), vincristine (NSC-67574), and hydroxyurea (NSC-32065). Cancer Treat Rep 1976; 60:601-609.
9. Luikart SD, Kennealey GT, Kirkwood JM. Randomized phase III trial of vinblastine, bleomycin and cis-dichlorodiammine-platinum versus dacarbazine in malignant melanoma. J Clin Oncol 1984; 2:164-168.
10. Chapman PB, Einhorn LH, Meyers ML, Saxman S, Destro AN, Panageas KS, et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 1999; 17:2745-2751.
11. Agarwala SS, Kirkwood JM. Interferons in melanoma. Curr Opin Oncol 1996; 8:167-174.
12. Falkson CI, Falkson G, Falkson HC. Improved results with the addition of interferon alfa-2b to dacarbazine in the treatment of patients with metastatic malignant melanoma. J Clin Oncol 1991; 9:1403-1408.
13. Thomson DB, Adena M, McLeod GRC, Mersey P, Gill PG, Coates AS, et al. Interferon-alfa-2a does not improve response or survival when combined with dacarbazine in metastatic malignant melanoma: results of a multi-institutional Australian randomized trial. Melanoma Res 1993; 3:133-138.
14. Falkson CI, Ibrahim J, Kirkwood JM, Coates AS, Atkins MB, Blum RH. Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study (E3690). J Clin Oncol 1998; 16:1743-1751.
15. Young AM, Marsden J, Goodman A, Burton A, Dunn JA. Prospective randomized comparison of dacarbazine (DTIC) versus DTIC plus interferon-alpha (IFN-alpha) in metastatic melanoma. Clin Oncol 2001; 13:458-465.
16. Bajetta E, DiLeo A, Zampino MG, Sertoli MR, Cornelia G, Barduagni M, et al. Multicenter randomized trial of dacarbazine alone or in combination with two different doses and schedules of interferon alfa-2a in the treatment of advanced melanoma. J Clin Oncol 1994; 12:806-811.
17. Hernberg M, Pyrhönen S, Muhonen T. Regimens with or without interferon-α as treatment for metastatic melanoma and renal cell carcinoma: an overview of randomized trials. J Immunother 1999; 22:145-154.
18. Huncharek M, Caubet JF, McGarry R. Single-agent DTIC versus combination chemotherapy with or without immunotherapy in metastatic melanoma: a meta-analysis of 3273 patients from 20 randomized trials. Melanoma Res 2001; 11:75-81.
19. Pyrhönen S, Hahka-Kemppinen M, Muhonen T. A promising interferon plus four-drug chemotherapy regimen for metastatic melanoma. J Clin Oncol 1992; 10:1919-1926.
20. Vuoristo M-S, Gröhn P, Kellokumpu-Lehtinen P, Kumpulainen E, Turunen M, Korpela M, et al. Intermittent interferon and polychemotherapy in metastatic melanoma. J Cancer Res Clin Oncol 1995; 121:175-180.
21. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47:207-214.
22. Allen IE, Kupelnick B, Kumashiro M, Luo D, Ross SD, Wolin MJ. Efficacy of interleukin-2 in the treatment of metastatic melanoma. Cancer Ther 1998; 1:168-173.
23. Barth A, Wanek LA, Morton DI. Prognostic factors in 1,521 melanoma patients with distant metastasis. J Am Coll Surg 1995; 181:193-201.
24. Atkins MB. Interleukin-2: clinical applications. Semin Oncol 2002; 29(Suppl. 7):12-17.
25. Rosenberg SA, Yang JC, Schwartzentruber J, Hwu P, Marincola FM, Topalian SL, et al. Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b. J Clin Oncol 1999; 17:968-975.
26. Eton O, Legha SS, Bedikian AY, Lee JJ, Buzaid AC, Hodges C, et al. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. J Clin Oncol 2002; 20:2045-2052.
27. Keilholz U, Conradt C, Legha SS, Khayat D, Scheibenbogen C, Thatcher N, et al. Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients. J Clin Oncol 1998; 16:2921-2929.
28. Ahmann DL, Creagan ET, Hahn RG, Edmonson JH, Bisel HF, Schaid DJ. Complete responses and long-term survivals after systemic chemotherapy for patients with advanced malignant melanoma. Cancer 1989; 63:224-227.
29. Sonnenblick M, Rosin A. Cardiotoxicity of interferon. Chest 1991; 99:557-561.